Autolus Therapeutics plc - Asset Resilience Ratio
Autolus Therapeutics plc (6A3A) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Autolus Therapeutics plc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Autolus Therapeutics plc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 6A3A asset base.
Liquid Assets Composition Over Time
This chart breaks down Autolus Therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Autolus Therapeutics plc debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €30.22 Million | 6.13% |
| Total Liquid Assets | €30.22 Million | 6.13% |
Asset Resilience Insights
- Limited Liquidity: Autolus Therapeutics plc maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Autolus Therapeutics plc Industry Peers by Asset Resilience Ratio
Compare Autolus Therapeutics plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Autolus Therapeutics plc (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Autolus Therapeutics plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.37% | €196.58 Million ≈ $229.82 Million |
€589.07 Million ≈ $688.68 Million |
-12.70pp |
| 2024-12-31 | 46.08% | €360.64 Million ≈ $421.63 Million |
€782.73 Million ≈ $915.09 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€375.38 Million ≈ $438.86 Million |
-- |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more